Galactosemia is an autosomal recessive inborn error of galactose metabolism, most commonly caused by deficiency of galactose-1-phosphate uridyltransferase (GALT) (classic galactosemia, Type I). It presents in the first 1–2 weeks of life after initiation of breast milk or lactose-containing formula, with a rapid, potentially fatal decline if untreated. [1-2] Incidence is approximately 1 in 30,000–60,000 live births in the US. [1] The following figure illustrates the pathophysiological mechanisms underlying both acute and chronic complications of GALT deficiency:
1. History
- Key HPI: Onset of symptoms within days of initiating milk feeds (breast milk or lactose-containing formula) [1-2]
- Symptom characterization: Poor feeding, vomiting, diarrhea, lethargy, failure to gain weight [2][4]
- Timing: Infants are born healthy; symptoms begin within the first week of life and progress rapidly [1][5]
- Progression: Can escalate from feeding difficulties to fulminant liver failure and septic shock within days if untreated [1]
- Important negatives: Ask about formula type (soy vs. milk-based), prior blood transfusions (can mask NBS results), family history of neonatal deaths or consanguinity [2][6]
2. Alarm Features
- Fulminant liver failure — jaundice, coagulopathy, hepatomegaly, abnormal bleeding [1-2]
- E. coli sepsis — a hallmark early complication; any neonate with E. coli sepsis should prompt consideration of galactosemia [2][6]
- Cataracts — may develop within days to weeks [1][4]
- Hypoglycemia — can be severe and contribute to neurologic injury [5]
- Encephalopathy/lethargy progressing to shock [1]
- Any neonate with unexplained liver failure + sepsis + feeding intolerance = galactosemia until proven otherwise [6]
3. Medications
- No pharmacologic cure exists; treatment is entirely dietary [7-8]
- Avoid medications containing lactose or galactose as excipients (common in many oral formulations) [5]
- Hormone replacement therapy (HRT) is needed for females with premature ovarian insufficiency (POI) [5]
- Calcium and vitamin D supplementation recommended to prevent decreased bone mineralization [5]
- Vitamin K supplementation may be needed, particularly in the acute neonatal phase with coagulopathy [5]
- Emerging therapies under investigation include GALK1 inhibitors, pharmacological chaperones, mRNA-based therapies, and aldose reductase inhibitors [9]
4. Diet
- Acute management: Immediately stop all galactose/lactose-containing feeds (breast milk, cow's milk formula) and switch to soy-based formula (e.g., Isomil®, Prosobee®) [1][5]
- Lifelong dietary restriction of dairy products and lactose-containing foods [5]
- Non-dairy foods with trace galactose (legumes, some fruits/vegetables) are generally considered acceptable for classic galactosemia [5][10]
- Epimerase deficiency (Type III): Do NOT use elemental formula — these patients may require trace environmental galactose for endogenous UDP-galactose biosynthesis; soy formula is preferred [10]
- Duarte galactosemia: Most providers no longer recommend dietary restriction, as current data suggest no increased risk of adverse outcomes [11]
- Hydration support is critical during the acute neonatal illness
5. Review of Systems
- GI: Vomiting, diarrhea, feeding refusal, abdominal distension
- Hepatic: Jaundice (prolonged/unconjugated and conjugated), hepatomegaly, bleeding/bruising
- Neurologic: Lethargy, hypotonia, seizures (if hypoglycemia), later — speech delay, ataxia, tremor [2][5]
- Ophthalmologic: Cataracts (may be bilateral) [1][4]
- Infectious: Fever, signs of sepsis (particularly E. coli) [2]
- Endocrine (females): Later in life — delayed puberty, amenorrhea (POI) [5]
- Growth: Failure to thrive, poor weight gain [2]
6. Collateral History and Family History
- Autosomal recessive inheritance — both parents are obligate carriers [1][7]
- Ask about consanguinity, prior neonatal deaths, or siblings with unexplained liver disease or developmental delay
- Irish Traveller population has an extremely high incidence (1 in 480 births) [1]
- African American patients with the p.S135L variant may have a milder clinical variant with better long-term outcomes [2]
- Prenatal diagnosis is available when familial GALT pathogenic variants are known [5]
7. Risk Factors
- Autosomal recessive inheritance — 25% recurrence risk per pregnancy for carrier parents [1]
- Ethnicity: Higher prevalence in Irish Traveller population; lower in Asian populations [1]
- Exposure to galactose: Breast milk or standard cow's milk formula is the trigger for acute disease [1-2]
- Delayed newborn screening results — infants may become symptomatic before NBS results return [6]
8. Differential Diagnosis
- Neonatal sepsis (other causes) — but E. coli sepsis in a neonate should specifically raise suspicion for galactosemia [2][6]
- Other metabolic causes of neonatal liver failure: hereditary fructose intolerance, tyrosinemia type I, mitochondrial hepatopathies [6]
- Biliary atresia — conjugated hyperbilirubinemia but typically without sepsis or reducing substances
- Neonatal hemochromatosis (gestational alloimmune liver disease)
- Citrin deficiency (can also cause false-positive NBS) [2]
- Fanconi-Bickel syndrome — can mimic galactosemia biochemically [11]
- Other galactosemia subtypes: GALK deficiency (Type II — cataracts only), GALE deficiency (Type III — variable severity) [2][4]
- Duarte galactosemia — ~25% GALT activity, generally clinically benign [2][11]
9. Past Medical History
- Typically presents in previously healthy neonates — no prior medical history [1]
- In older patients presenting atypically, inquire about: prior episodes of liver dysfunction, cataracts, developmental delay, speech difficulties, or history of premature ovarian insufficiency [5]
- Surgical history: Prior cataract surgery may be a clue to undiagnosed galactosemia
- Transfusion history: RBC transfusion prior to NBS can cause falsely normal GALT activity — molecular testing is preferred in this scenario [2][6]
10. Physical Exam
- Vital signs: Fever (sepsis), tachycardia, hypotension (shock), hypothermia in neonates
- General: Ill-appearing, lethargic, poor tone
- Eyes: Bilateral cataracts (oil-droplet appearance on slit lamp) [1][4]
- Abdomen: Hepatomegaly, abdominal distension, ascites (in advanced liver failure)
- Skin: Jaundice, petechiae/purpura (coagulopathy), poor skin turgor
- Neurologic: Hypotonia, poor suck reflex; in older children — tremor, ataxia, dystonia [5]
- Growth parameters: Weight loss, failure to thrive
11. Lab Studies
- Newborn screening (NBS): GALT enzyme activity in dried blood spots ± total galactose (galactose + Gal-1-P) [2]
- Confirmatory testing:
- Erythrocyte GALT enzyme activity — absent or barely detectable in classic galactosemia [5]
- Erythrocyte galactose-1-phosphate (Gal-1-P) — usually >10 mg/dL (can be >120 mg/dL); normal <1 mg/dL [5]
- GALT gene molecular sequencing — identifies pathogenic variants (most common: p.Gln188Arg in Europeans) [2]
- Must draw blood for GALT enzyme assay BEFORE any RBC transfusion [6]
- Urine reducing substances — positive (non-glucose reducing substance = galactose); a classic bedside clue [6]
- Liver function tests: Elevated AST/ALT, direct and indirect bilirubin, coagulopathy (elevated PT/INR)
- CBC: Leukocytosis or leukopenia (sepsis)
- Blood cultures: Particularly for E. coli
- Blood glucose: Hypoglycemia
- Renal function: May show tubular dysfunction
- Monitoring: Erythrocyte Gal-1-P and urinary galactitol for ongoing dietary compliance [5][10]
12. Imaging
- Not typically required for diagnosis
- Abdominal ultrasound: May show hepatomegaly, hepatic steatosis, or ascites in acute liver failure
- Brain MRI (older patients): May reveal white matter volume loss, cerebellar atrophy, and structural changes associated with long-term neurologic complications [12]
- DEXA scan: Consider in older patients for osteoporosis screening given calcium/vitamin D concerns [5]
13. Special Tests
- Slit-lamp examination: To detect cataracts (oil-droplet cataracts may be reversible with early dietary treatment) [1][4]
- Isoelectric focusing/electrophoresis: Historically used to identify Duarte variant; now largely replaced by molecular testing [2]
- Urinary galactitol: Elevated; useful for monitoring [10]
- Prenatal diagnosis: Available via chorionic villus sampling or amniocentesis when familial variants are known [5]
- Carrier testing: GALT enzyme activity ~50% of normal in heterozygotes; molecular testing preferred [2]
14. ECG
- Not a primary feature of galactosemia
- ECG may be indicated in the setting of septic shock to evaluate for arrhythmias or myocardial dysfunction
- No galactosemia-specific ECG findings
15. Assessment
Classic galactosemia (Type I) is a metabolic emergency in the neonatal period. The clinical triad of **jaundice + hepatomegaly + E. coli sepsis in a neonate receiving milk feeds is highly suggestive. [1-2][6]
- Severity stratification:
- Acute neonatal crisis (liver failure, sepsis, coagulopathy) = critical/emergent
- Positive NBS in asymptomatic infant = urgent — immediate dietary change while awaiting confirmatory testing [5]
- Duarte galactosemia = generally benign, no treatment recommended [11]
- Atypical presentations: Clinical variant galactosemia (common in African Americans with p.S135L) may present with milder symptoms and can be missed on NBS if only total galactose is measured [2][5]
- Long-term complications despite treatment: Speech dyspraxia/dysarthria, cognitive impairment, ataxia/tremor, and POI in ~85% of females — these are not preventable with diet alone [5][13-14]
16. Treatment Plan
Acute stabilization (neonatal crisis)
- Immediately discontinue all galactose/lactose-containing feeds — switch to soy-based formula [1][5]
- IV fluids with dextrose for hypoglycemia
- Broad-spectrum antibiotics (covering E. coli and Gram-negatives) if sepsis is suspected
- Correct coagulopathy with vitamin K, FFP as needed
- Supportive ICU care for liver failure/shock
Ongoing management
- Lifelong galactose-restricted diet — eliminate all dairy; soy-based formula in infancy [5]
- Calcium, vitamin D, and vitamin K supplementation [5]
- Surveillance schedule per GeneReviews: [5]
- Biochemical genetics clinic every 3 months in the first year, every 6 months in the second year, then annually
- Monitor erythrocyte Gal-1-P and urinary galactitol
- Ophthalmologic exams for cataracts
- Developmental assessment at age 1 year; speech therapy for childhood apraxia of speech
- Monitor for POI in females (FSH, LH, estradiol); HRT as needed
- Bone density monitoring
- Cataract surgery rarely needed if diet initiated early [5]
17. Disposition
- Admit any neonate with suspected galactosemia presenting with liver failure, sepsis, coagulopathy, or hemodynamic instability — NICU level care [6]
- Admit for observation if NBS is positive and infant is symptomatic, even mildly
- Outpatient management appropriate for:
- Asymptomatic infants with positive NBS awaiting confirmatory testing (with immediate dietary switch to soy formula)
- Established patients on galactose-restricted diet with stable monitoring
- Specialist consultation triggers:
- Metabolic/biochemical genetics — all confirmed or suspected cases [5]
- Pediatric hepatology — if liver failure
- Pediatric infectious disease — if E. coli sepsis
- Ophthalmology — cataract evaluation
- Speech-language pathology — early referral for speech apraxia
- Reproductive endocrinology — for females with POI
18. Follow Up / Return Precautions
- Follow-up timing: Biochemical genetics clinic every 3 months in the first year of life [5]
- Return immediately for: Poor feeding, vomiting, jaundice, lethargy, fever, or any signs of illness — these infants are vulnerable to metabolic decompensation with intercurrent illness
- Patient/family counseling:
- Galactosemia is a lifelong condition requiring strict dietary adherence
- Long-term complications (speech, cognitive, motor, POI) may develop despite perfect dietary compliance — this is not a failure of treatment [5][13-14]
- Genetic counseling for family planning (25% recurrence risk per pregnancy; prenatal diagnosis available) [5]
- Educate on reading food labels for hidden sources of lactose/galactose, including medications [5]
- Expected course: Acute neonatal symptoms resolve rapidly with dietary change; long-term developmental trajectory is variable and not fully predictable in infancy [5]
References
1. Newborn Screening for Galactosaemia. — Lak R, Yazdizadeh B, Davari M, Nouhi M, Kelishadi R. The Cochrane Database of Systematic Reviews. 2020.
2. Laboratory Diagnosis of Galactosemia: A Technical Standard and Guideline of the American College of Medical Genetics and Genomics (ACMG). — Pasquali M, Yu C, Coffee B. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2018.
3. Galactose‐1‐phosphate uridyltransferase deficiency: A literature review of the putative mechanisms of short and long‐term complications and allelic variants. — Viggiano E, Marabotti A, Politano L, Burlina A. Clinical Genetics. 2018.
4. Galactosemia. — National Library of Medicine (MedlinePlus) 2015.
5. Classic Galactosemia and Clinical Variant Galactosemia. — Berry GT GeneReviews® [Internet]. 2021.
6. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Diagnosis and Management of Pediatric Acute Liver Failure. — Squires JE, Alonso EM, Ibrahim SH, et al. Journal of Pediatric Gastroenterology and Nutrition. 2022.
7. Galactosemia: Biochemistry, Molecular Genetics, Newborn Screening, and Treatment. — Succoio M, Sacchettini R, Rossi A, Parenti G, Ruoppolo M. Biomolecules. 2022.
8. Hereditary Galactosemia. — Demirbas D, Coelho AI, Rubio-Gozalbo ME, Berry GT. Metabolism: Clinical and Experimental. 2018.
9. Reshaping the Treatment Landscape of a Galactose Metabolism Disorder. — Rubio-Gozalbo ME, Naomi Vos E, Rivera I, Lai K, Berry GT. Journal of Inherited Metabolic Disease. 2025.
10. Epimerase Deficiency Galactosemia. — Fridovich-Keil J, Bean L, He M, et al GeneReviews® [Internet]. 2021.
11. Duarte Galactosemia. — Fridovich-Keil JL, Gambello MJ, Singh RH, et al GeneReviews® [Internet]. 2025.
12. Myo-Inositol Deficiency, Structural Brain Changes, and Cerebral Perfusion Alterations in Classic Galactosemia: Preliminary Insights From a Multiparametric MRI Study. — Niess E, Niess F, Bogner W, et al. Journal of Inherited Metabolic Disease. 2025.
13. Heritability of Long-Term Complications in Classic Galactosemia. — Garrett OS, Smith NH, Cutler DJ, et al. Journal of Inherited Metabolic Disease. 2026.
14. Brain Function in Classic Galactosemia, a Galactosemia Network (GalNet) Members Review. — Panis B, Vos EN, Barić I, et al. Frontiers in Genetics. 2023.